BENEFITS 
In the preliminary human trials, patients have shown an increase in white cell production following the 
administration of rhIL-3 and rhGM-CSF. When used together with the addition of peripheral blood 
infused with your marrow, we hope that increased white cell and platelet production will result in 
earlier engraftmenL Earlier engraftment may reduce infection and Weeding complications allowing 
earlier discharge and possibly improve survivaL This treatment may show that the anticipated benefits 
do not occur. Although we expect this treatment to benefit your condition, there is no guarantee that it 
will do so, and it is possible that you may have unfavorable complications as a result of this treatment 
ALTERNATIVES 
You may choose not to participate, in which case you would receive standard BMT treatment 
OTHER INFORMATION 
Your decision to participate in this study is voluntary and you may withdraw your consent at any time, 
for any reason, without notice and without prejudice. 
It is understood that all medical expenses relating to, or arising from, these procedures will be paid by 
you and/or your insurance company. However, rhll^3 will be provided at no cost to you by the 
manufacturer. 
Financial compensation is not available in the event of physical injury, adverse effects, or death 
resulting from this research project. Medical care will be authorized by the attending -physician. You 
and/or your insurance company will be responsible for all costs arising from the medical care. 
In order to evaluate the results of this study, your medical records will need to be available to other 
physicians and researchers associated with the research project at FHCRC. The Food and Drug 
Administration, Sandoz Corporation (which produces rhJL-3), Immunex Corporation (which produces 
rhGM-CSF) and the National Institutes of Health will also have access to this information. All 
precautions to maintain confidentiality of medical records will be taken. Your personal identity will not 
be revealed in any publication or results. Study records will be maintained indefinitely for the purpose 
of analysis and follow-up. 
If you have questions about the research please contact your attending physician. If you have any 
questions about your rights as a research participant, please contact Karen Hansen in the Institutional 
Review Office of the Fred Hutchinson Cancer Research Center at 206/667-4867. 
Investigator Statement 
I have provided an explanation of the above research program. The subject was given an opportunity to 
discuss the procedures, including possible alternatives, and to ask any additional questions. A signed 
[340] 
Recombinant DNA Research, Volume 16 
